Is Nintedanib now FDA approved for treating Idiopathic Pulmonary Fibrosis in adults?
Yes, the FDA approved nintedanib capsules for treating idiopathic pulmonary fibrosis in adults in 2014.
Read the full answer →Can genetic risk tests for Idiopathic Pulmonary Fibrosis work well for non-European people?
Genetic risk tests for idiopathic pulmonary fibrosis work best for people of European ancestry, but they show limited accuracy for non-European groups because most studies have focused on European populations.
Read the full answer →Is Xarelto approved for treating venous thromboembolism and preventing pulmonary embolism?
Yes, Xarelto (rivaroxaban) is FDA-approved for treating deep vein thrombosis and pulmonary embolism, and for preventing recurrent venous thromboembolism.
Read the full answer →What is the major bleeding rate for home treatment of cancer pulmonary embolism?
For low-risk cancer patients with pulmonary embolism, home treatment shows a major bleeding rate of about 4.6% within 3 months, based on the ONCO PE trial.
Read the full answer →Does getting extra pharmaceutical care help manage my COPD better?
Yes, extra pharmaceutical care — like nurse-led telecare teams — can improve quality of life and reduce hospital visits for people with COPD.
Read the full answer →Will adding balance training to my rehab improve my COPD stability?
Yes, adding balance training to pulmonary rehabilitation improves balance, confidence, and quality of life in COPD patients, based on multiple randomized trials.
Read the full answer →Can a nurse and social worker telecare team improve quality of life for high-risk COPD patients?
Yes, a nurse and social worker telecare team improved quality of life, depression, and anxiety in high-risk COPD patients in a randomized trial.
Read the full answer →Does a higher dietary inflammatory index increase the risk of developing COPD according to recent studies?
Yes, recent studies consistently show that a higher dietary inflammatory index (DII) is linked to an increased risk of developing COPD, with each unit increase in DII raising risk by 5-8%.
Read the full answer →Is Breztri Aerosphere approved by the FDA for maintenance treatment of Chronic Obstructive Pulmonary Disease?
Yes, Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is FDA-approved for maintenance treatment of COPD. It is not for acute bronchospasm or asthma.
Read the full answer →Does adding balance training to pulmonary rehabilitation help older COPD patients improve their balance?
Yes, adding balance training to pulmonary rehabilitation significantly improves balance in older COPD patients, based on a 2024 meta-analysis.
Read the full answer →